Master protocol for mantle cell lymphomaA multicenter phase II trial testingGemcitabine for the treatment of patients with newlydiagnosed, relapsed or chemotherapy resistantmantle cell lymphomaProtocol SAKK 36/03
- Conditions
- patients with newlydiagnosed, relapsed or chemotherapy resistant mantle cell lymphomaMedDRA version: 6.1Level: HLGTClassification code 10025323
- Registration Number
- EUCTR2004-002860-43-IT
- Lead Sponsor
- SIAK
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method